We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific ...

Korro Bio (KRRO) announced the appointment of Loic Vincent, Ph.D., as the Company’s Chief Scientific Officer. Prior to joining Korro, Dr.

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

For example, biotech and mining... CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports.

RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...

Read Our Latest Stock Report on KRRO Korro Bio Stock Performance Shares of KRRO opened at $23.76 on Friday. Korro Bio has a one year low of $18.50 and a one year high of $98.00. The firm has a 50 ...

Korro Bio completed dosing for its KRRO-110 study in AATD, expects interim results in 2025, and has strong financial resources. Korro Bio, Inc. has completed dosing for the first two cohorts in ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative ...

Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). This designation highlights ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing therapies, has been making significant strides in the development of treatments for rare genetic disorders, ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading.